Aug 2013 to 2000 Senior Lead Management ConsulantSAIC McLean, VA Mar 2013 to Jul 2013 Strategic Business PlannerNJVC Vienna, VA Apr 2011 to May 2011 Proposal ManagerBooz Allen Hamilton Herndon, VA Apr 2009 to Mar 2011 Senior ConsultantUS Army Fort Meade, MD Mar 1996 to Apr 2008 MI Systems Integrator / Maintainer
Education:
University of Maryland University College 2009 M.B.A.University of Maryland University College 2007 B.S. in Business AdministrationRio Salado Community College 2002 A.A.S. in Computer Information Systems
Skills:
MS Operating Systems and Office Applications (SharePoint, Project 2010, Word, Excel, Power Point, Access)
Athens High School - General/Biology, Lincoln Land Community College - Biology
Relationship:
In_a_relationship
Tagline:
Im a 28 year old professional photographer from the Springfield Illinois. I am also a volunteer Firefighter/EMT. I will be updateing this as I have time anymore questions just ask.
Bragging Rights:
D&D PHOTOGRAPHY ~ OWNER
Andrew Dillon
Work:
Dillons Resturaunt - Dishwasher/Side Cook Fairhaven Little League - Umpire
Education:
Fairhaven High School
Andrew Dillon
Education:
Loyola University Chicago - Advertising/ PR
Andrew Dillon
Work:
I.D. Booth / Booth Electric Supply - Manager & Sales
About:
I'm currently managing the Corning, NY branch Of I.D. Booth/ Booth Electric Supply. Â I've been with Booth for 4 years but in the electrical supply business for 13.
Tagline:
Branch Manager Of Corning, NY Location
Andrew Dillon
Education:
Taylor University - Computer Science
Andrew Dillon
Andrew Dillon
Andrew Dillon
Flickr
News
NICE Reverses Stand on Abiraterone After Janssen Submits Additional Data
ng insufficient evidence to prove value. We know how important it is for patients to have the option to delay chemotherapy and its associated side effects, so we are disappointed not to be able to recommend abiraterone for use in this way, Andrew Dillon, chief executive of NICE, has said in a
Date: Mar 21, 2016
Category: Health
Source: Google
Roche's bid to sub Kadcyla for Herceptin takes a big hit with lackluster PhIII data
company's heralded breast cancer treatment was too expensive to cover. Roche proposed a discount to its list price, but Kadcyla costs 90,831 ($142,000) for a 14.5 month course of treatment, leaving it well above the cost-effectiveness threshold for cancer drugs, NICE CEO Andrew Dillon said at the time.
Date: Dec 19, 2014
Category: Health
Source: Google
NICE set to block use of 'unaffordable' new breast cancer drug
NICE chief executive Sir Andrew Dillon said he hoped Roche would act in the best interest of patients and use the consultation period to look again at their evidence and consider if there was more they could do.
The rationale for the draft guidelines is that the drug is very costly and it's not clear which patients are likely to benefit, according to Andrew Dillon, chief executive of the National Institute for Health & Clinical Excellence, which decides which drugs will be financed from public funds.